NZ513450A - Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents - Google Patents

Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents

Info

Publication number
NZ513450A
NZ513450A NZ513450A NZ51345000A NZ513450A NZ 513450 A NZ513450 A NZ 513450A NZ 513450 A NZ513450 A NZ 513450A NZ 51345000 A NZ51345000 A NZ 51345000A NZ 513450 A NZ513450 A NZ 513450A
Authority
NZ
New Zealand
Prior art keywords
purin
cyclopentene
cis
amino
phosphoramidate
Prior art date
Application number
NZ513450A
Other languages
English (en)
Inventor
Susan Mary Daluge
Christopher Mcguigan
Original Assignee
Glaxo Group Ltd
Univ College Cardiffconsultant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903090.0A external-priority patent/GB9903090D0/en
Application filed by Glaxo Group Ltd, Univ College Cardiffconsultant filed Critical Glaxo Group Ltd
Publication of NZ513450A publication Critical patent/NZ513450A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ513450A 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents NZ513450A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9903090.0A GB9903090D0 (en) 1999-02-12 1999-02-12 Therapeutic compounds
US17020599P 1999-12-10 1999-12-10
PCT/EP2000/001045 WO2000047591A1 (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents

Publications (1)

Publication Number Publication Date
NZ513450A true NZ513450A (en) 2004-03-26

Family

ID=26315118

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ513450A NZ513450A (en) 1999-02-12 2000-02-10 Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents

Country Status (24)

Country Link
US (1) US7115590B1 (enExample)
EP (1) EP1150988B1 (enExample)
JP (1) JP2002536452A (enExample)
KR (1) KR20010102082A (enExample)
CN (1) CN1346360A (enExample)
AR (1) AR031975A1 (enExample)
AT (1) ATE241633T1 (enExample)
AU (1) AU772478B2 (enExample)
BR (1) BR0008135A (enExample)
CA (1) CA2362662A1 (enExample)
CZ (1) CZ20012908A3 (enExample)
DE (1) DE60002986T2 (enExample)
DK (1) DK1150988T3 (enExample)
DZ (1) DZ3007A1 (enExample)
ES (1) ES2200820T3 (enExample)
HK (1) HK1039337B (enExample)
HU (1) HUP0105476A3 (enExample)
IL (1) IL144647A0 (enExample)
NO (1) NO20013910L (enExample)
NZ (1) NZ513450A (enExample)
PL (1) PL204458B1 (enExample)
PT (1) PT1150988E (enExample)
TR (1) TR200102313T2 (enExample)
WO (1) WO2000047591A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
JP2003516408A (ja) * 1999-12-10 2003-05-13 グラクソ グループ リミテッド 抗ウィルス薬としての（１Ｒ，シス）−４−［４−アミノ−７Ｈ−ピロロ（２，３−ｄ）ピリミジン−７−イル］−２−シクロペンテン−１−メタノール類縁物
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
HRP20030047B1 (hr) † 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
GB0129945D0 (en) * 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions
WO2026151964A1 (en) 2025-01-10 2026-07-16 Atea Pharmaceuticals, Inc. Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP2003516408A (ja) * 1999-12-10 2003-05-13 グラクソ グループ リミテッド 抗ウィルス薬としての（１Ｒ，シス）−４−［４−アミノ−７Ｈ−ピロロ（２，３−ｄ）ピリミジン−７−イル］−２−シクロペンテン−１−メタノール類縁物
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Also Published As

Publication number Publication date
US7115590B1 (en) 2006-10-03
PL204458B1 (pl) 2010-01-29
DK1150988T3 (da) 2003-09-29
NO20013910L (no) 2001-10-10
DE60002986D1 (en) 2003-07-03
ATE241633T1 (de) 2003-06-15
WO2000047591A1 (en) 2000-08-17
BR0008135A (pt) 2002-02-19
KR20010102082A (ko) 2001-11-15
IL144647A0 (en) 2002-05-23
NO20013910D0 (no) 2001-08-10
PT1150988E (pt) 2003-10-31
HUP0105476A2 (en) 2002-06-29
TR200102313T2 (tr) 2002-03-21
EP1150988B1 (en) 2003-05-28
CZ20012908A3 (cs) 2002-10-16
EP1150988A1 (en) 2001-11-07
HUP0105476A3 (en) 2002-08-28
DZ3007A1 (fr) 2003-03-27
ES2200820T3 (es) 2004-03-16
AU772478B2 (en) 2004-04-29
AU2671300A (en) 2000-08-29
HK1039337B (en) 2003-11-21
CA2362662A1 (en) 2000-08-17
JP2002536452A (ja) 2002-10-29
PL350023A1 (en) 2002-10-21
AR031975A1 (es) 2003-10-22
HK1039337A1 (en) 2002-04-19
DE60002986T2 (de) 2004-05-19
CN1346360A (zh) 2002-04-24

Similar Documents

Publication Publication Date Title
PL350023A1 (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents
IL112539A (en) Chloropyrimidine intermediates for preparing-2-aminopurine nucleoside analogues and their preparation
HUP0301112A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY126527A (en) Novel dihydropyrimidines
WO2002091989A3 (en) Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
GEP20084545B (en) Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection
AU2001248331A1 (en) Medicaments against viral diseases
ATE333284T1 (de) Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
WO2001051083A3 (en) Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU2002364730A8 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
NO20020931L (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
ZA200108283B (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs.
AU5173501A (en) Polyamine analogues as cytotoxic agents
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
PL356640A1 (en) Treatment of viral infections using levovirintm
NO931011L (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
WO2008118879A3 (en) Antiviral compositions comprising 2 compounds
BRPI0417513A (pt) agentes combinados de chp-gemcitabina e seu uso como substáncias antitumorais ativas
CA98132S (en) Tabletop folder/inserter
ZA200106551B (en) Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents.
GB9903091D0 (en) Therapeutic nucleoside compound
AU2068901A (en) Analogs of (1s, cis)-4-(2-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral
EP1143981A4 (en) TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)